Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-02-22
2011-02-22
Bunner, Bridget E (Department: 1649)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C530S350000, C530S387100, C530S387300, C530S388100, C530S389100, C514S019300
Reexamination Certificate
active
07892541
ABSTRACT:
Embodiments of the present invention relate to p110 soluble EGFR (p110 sEGFR) peptides and nucleic acid sequences. Antibodies, methods of detection, kits, and expression vectors for p110 sEGFR are disclosed. In addition, assays on biological samples for determining and evaluating risk assessment and cancer prevention, screening and early detection, diagnosis, prognosis, theragnosis, monitoring of responsiveness to treatment, and monitoring of disease progression, recurrence, or metastasis of a cancer, are disclosed. In examples, a lower p110 sEGFR concentration adjusted for demographical and physiological variables and other biomarkers is associated with cancer. Therapeutics and methods of treating a cancer related to p110 sEGFR also are embodied herein.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4741900 (1988-05-01), Alvarez et al.
patent: 4816537 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5183884 (1993-02-01), Kraus
patent: 5252348 (1993-10-01), Schreier et al.
patent: 5258498 (1993-11-01), Huston et al.
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5674618 (1997-10-01), Lee et al.
patent: 5708156 (1998-01-01), Ilekis
patent: 5766625 (1998-06-01), Schreier et al.
patent: 5807683 (1998-09-01), Brenner
patent: 2003/0219842 (2003-11-01), Carney et al.
patent: 2007/0042405 (2007-02-01), Lokshin
patent: 125023 (1984-11-01), None
patent: 173494 (1986-03-01), None
patent: 184187 (1986-06-01), None
patent: 171496 (1989-02-01), None
patent: 8601533 (1986-03-01), None
patent: 8702671 (1987-05-01), None
Mayes et al., The EMBO Journal, 1984; 3: 531-537.
Hennekens, C.H., and Buring, J.E. Screening in: S.L. Mayrent (ed.) Epidemiology in Medicine, pp. 327-347 (Ch. 13) Boston; Little, Brown, 1987.
Gatineau, M., et. al., Phase II combination of gefitinib and docetaxel for advanced or metastatic non-small cell lung cancer: clinical results and biological monitoring, Targeted Oncology, vol., 1, No. 3, Jul. 2006.
Kong, Y. et al., Elevated soluble epidermal growth factor recepter level in pituitary adenoma and carcinoma, Chin Med Sci J. Sep. 2004; 19(3): 199-202.
Li, S. et al., Structural basis for inhibition of the epidermal growth factor receptor by cetuximab., Cancer Cell, Apr. 2005; 7(4): 301-11.
Hudelist, G., et al., Serum EGFR levels and efficacy of trastuzumab-based therapy in patients with metastatic breast cancer., Eur J Cancer, Jan. 2006; 42(2); 186-92. Epub Dec. 2, 2005.
Müller, V., et al., Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer, Anticancer Res. Mar.-Apr. 2006; 26(2B): 1479-87.
Witzel I., et al., Clinical utility of determination of HER-2
eu and EGFR fragments in serum of patients with metastatic breast cancer, Int J Biol Markers. Jul.-Sep. 2006;21(3):131-40.
Sandri, MT, Serum EGFR and serum HER-2
eu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy, Cancer, Aug. 1, 2007; 110(3); 509-517.
Chudecka-Glaz, A, et al., Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary, Arch Gynecol Obstet. Nov. 2004;270(3): 151-76. Epub Jul. 23, 2003.
Krämer, S., et al., Gonadotropin levels in ovarian cyst fluids: a predictor of malignancy?, Int J Biol Markers. Jul.-Sep. 1998; 13(3): 165-8.
Zampino, M.G., et al., Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with getfitinib?, Cancer, DOI 10.1007/s00280-008-0722-x, 2008.
Gregorc, V., et al., Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer, Clinical Cancer Research, 6006 vol. 10, 6006-6012, Sep. 2004.
Linkov, F., et al., Early Detection of Head and Neck Cancer: Development of a Novel Screening Tool Using Multiplexed Immunobead-Based Biomarker Profiling, Cancer Epidemiol Biomarkers Prev 2007; 16(1). Jan. 1, 2007.
Lafky, J., et al., Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer, Science Direct, Biochimica et Biophysica Acta 1785 (2008) 232-265.
Baron, A., et al., A Preliminary Study of Serum Concentrations of Soluble Epidermal Growth Factor Receptor (sErbB1), Gonadotropins, and Steroid Hormones in Healthy Men and Women, Cancer Epidemiology Biomarkers & Prevention vol. 10, 1175-1185, Nov. 2001.
Adelman et al., In Vitro Mutagenesis (DNA 2:183, 1983).
Felgner et al., Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure Annals N. Y. Acad. Sci. 772:126-139, 1995).
Arnon et al., “Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy”, in Monoclonal Antibodies and Cancer Therapy, Reisfeld et al. (eds.), pp. 243-256 (Alan R. Liss, Inc. 1985).
Ausubel et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY (1994) .
Baron et al., Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer1 J. Immunol. Methods, 219, 23 (1998).
Baron, A.T., et al., Cancer Epidemiol Biomarkers Prev, 14: 306-18, 2005 .
Beidler et al., 1988, J. Immunol. 141:4053-4060.
Better et al., 1988, Science 240:1041-1043.
Bird, 1988, Science 242:42342.
Boussif et al., PNAS 92:7297-7301, 1995 .
Chen et al, Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature, 32, 820 (1987).
Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96.
Coussens et al., Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230, 1132 (1988).
Cunningham and Wells, High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis (Science 244:1081-1085, 1989).
Curiel et al. 1992 Am. J. Respir. Cell Mol. Biol. 6:247-52.
Das et al., Endocrinology 134,971 (1994).
Felgner et al., Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure PNAS 84:7413-7417, 1987.
Flickinger et al., Mol. Cell, Biol., 12, 883 (1992).
Goeddel et al., Synthesis of human fibroblast interferon byE. coilNucleic Acids Res., 8, 4057 (1980).
Hellstrom et al., “Antibodies for Drug Delivery”, in Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.), pp. 623-653 (Marcel Dekker, Inc. 1987).
Hendler et al, Proc. Am. Soc. Clin. Oncol., 8, 223 (1989).
Hennekens, C. H. and Buring (1987). Screening. Epidemiology in Medicine. S.L. Mayrent. Boston : Little, Brown: 327-47 (Chapter 13) Boston: Little, Brown.
Huang, L., L. O. Gainkam, et al. (2008) Mol Imaging Biol 10(3): 167-75.
Hunts et al., Cell Mol. Genet., 11, 477 (1988).
Huston et al., 1988, Proc. Natl. Acad. Sci, USA 85:5879-5883.
Huston et al., Methods in Enzymology 203:46-88 (1991).
Hyrup et al, Bioorganic & Medicinal Chemistry, 4:523, 1996.
Ilekis et al., Mol. Reprod. Devel., 41, 149 (1995).
Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109.
Izant J. G. and Weintraub H., (Cell, 36: 100.7-1015, 1984) .
Jones et al., 1986, Nature 321:552-525.
Kohler, 1980, Proc. Nat'l Acad. Sci. USA 77:2197.
Kohler and Milstein, 1975, Nature 256:495-497.
Kozbor et al., 1983, Immunology Today 4:72.
Kutmeier et al. (1994, BioTechniques 17:242).
Lam, 1997, Anticancer Drug Des. 12:145; U.S. Appl. No, 5,738,996.
Lax et al., Cell Regul. 2,337 (1991).
Leitzel et al., J. Clin. Oncol., 13, 1129 (1995).
Liu et al., 1987, J. Immunol. 139:3521-3526.
Liu et al., 1987, Proc. Nati. Acad. Sci, USA 84:3439-3443.
Lonberg and Huszar Human antibodies from transgenic mice (1995, Int, Rev.
Baron Andre
Maihle Nita J.
Reiter Jill
Borgeest Christina
Bunner Bridget E
Cohen & Grigsby P.C.
Tumor Biology Investment Group, Inc.
LandOfFree
Soluble epidermal growth factor receptor isoforms does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble epidermal growth factor receptor isoforms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble epidermal growth factor receptor isoforms will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2642155